Beta Bionics shares fall as company prices $150M stock offering at $17.25/share
At a glance
- $BBNX today−7.37%last $15.21
- Vs industry peers−5.69 pts6-peer median −1.68% · far behind
- Since Sep 16−31.4%from the first trade after the story
- 52-week range72.8% above low$8.80 – $32.71
- Cash runway~14 mo$81.6M cash ÷ $5.7M/mo burn · 10-Q
- In the headline$150 millionAmount
Nothing reported about beta bionics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: This one turns on a concrete figure ($17.25); set it against the recent trend before reading it as a turning point.
- How the stock is trading: $BBNX -7.37% in the latest session.
- Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Where the stock stands
Beta Bionics ($BBNX) fell 7.37% to $15.21 in the latest session. Over the past month it is down 9.7%. That leaves it 54% below its 52-week high of $32.71 and 73% above its low of $8.80. It has been a volatile year: the high was 3.7 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Oct 27, 2026), $BBNX lost $24.4M over the quarter to Sep 30, 2026 on revenue of $35.5M (+10.9% QoQ). Operations used $50.7M of cash over the nine months to Sep 30, 2026 — about $5.7M a month — against $81.6M in cash on Sep 30, 2026. At that pace the cash covers about 14 months. Total liabilities were $42.4M against $81.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Sep 17, 1 day after this story; it is $BBNX's own account and the first thing to read. Figures are as filed with the SEC; the $BBNX page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Beta Bionics in the last 30 days. It reads neutral.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
For the company's side of it, read its latest SEC filings on the $BBNX page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $BBNX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on September 16, 2026. $BBNX has moved -31.42% ($22.18 to $15.21). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
